Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Pollard

Showing results (631-640 of 642) with videos related to

Pageof 65
Sort By:
Plos Pathogens|March 26, 2016
Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialSergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, et al.
AIDS (London, England)|November 26, 2019
Delayed gastrointestinal-associated lymphoid tissue reconstitution in duodenum compared with rectum in HIV-infected patients initiating antiretroviral therapyTalia Sainz, Sergio Serrano-Villar, Surinder Mann, et al.
Plos Pathogens|May 4, 2017
Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialSergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, et al.
Plos Pathogens|January 23, 2016
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialSergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, et al.
The New England Journal of Medicine|December 12, 2003
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infectionGregory K Robbins, Victor De Gruttola, Robert W Shafer, et al.
Plos One|February 27, 2015
C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settingsMark W Tenforde, Nikhil Gupte, David W Dowdy, et al.
Molecular Biology of the Cell|January 30, 2016
From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutationsGudio Veit, Radu G Avramescu, Annette N Chiang, et al.
Nature Communications|March 16, 2022
Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genesIndu Kohaar, Xijun Zhang, Shyh-Han Tan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2015
Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort StudyAshwin Balagopal, David M Asmuth, Wei-Teng Yang, et al.
Cell Reports. Medicine|November 17, 2022
Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathwaysAnthony R Soltis, Nicholas W Bateman, Jianfang Liu, et al.
Pageof 65

Showing results (631-640 of 642) with videos related to

Sort By:
Pageof 65
Plos Pathogens|March 26, 2016
Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialSergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, et al.
AIDS (London, England)|November 26, 2019
Delayed gastrointestinal-associated lymphoid tissue reconstitution in duodenum compared with rectum in HIV-infected patients initiating antiretroviral therapyTalia Sainz, Sergio Serrano-Villar, Surinder Mann, et al.
Plos Pathogens|May 4, 2017
Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialSergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, et al.
Plos Pathogens|January 23, 2016
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialSergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, et al.
The New England Journal of Medicine|December 12, 2003
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infectionGregory K Robbins, Victor De Gruttola, Robert W Shafer, et al.
Plos One|February 27, 2015
C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settingsMark W Tenforde, Nikhil Gupte, David W Dowdy, et al.
Molecular Biology of the Cell|January 30, 2016
From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutationsGudio Veit, Radu G Avramescu, Annette N Chiang, et al.
Nature Communications|March 16, 2022
Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genesIndu Kohaar, Xijun Zhang, Shyh-Han Tan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2015
Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort StudyAshwin Balagopal, David M Asmuth, Wei-Teng Yang, et al.
Cell Reports. Medicine|November 17, 2022
Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathwaysAnthony R Soltis, Nicholas W Bateman, Jianfang Liu, et al.
Pageof 65